TR200100205T2 - Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması. - Google Patents

Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması.

Info

Publication number
TR200100205T2
TR200100205T2 TR2001/00205T TR200100205T TR200100205T2 TR 200100205 T2 TR200100205 T2 TR 200100205T2 TR 2001/00205 T TR2001/00205 T TR 2001/00205T TR 200100205 T TR200100205 T TR 200100205T TR 200100205 T2 TR200100205 T2 TR 200100205T2
Authority
TR
Turkey
Prior art keywords
acat
administration
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
TR2001/00205T
Other languages
English (en)
Inventor
Michael Andrew Bocan Thomas
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200100205T2 publication Critical patent/TR200100205T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Bu bulus bir memelide aterosklerotik lezyonlarin histiosit ve düz kas hücresi bilesenini azaltmak, böylece var olan lezyonlarin genislemesini ve yeni lezyonlarin gelismesini önlemek için ve plak kopmasini engellemek ve lezyon gerilemesini tesvik etmek için ACAT ve MMP inhibitörlerinin birlikte uygulanmasina iliskindir.
TR2001/00205T 1998-07-21 1999-06-18 Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması. TR200100205T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
TR200100205T2 true TR200100205T2 (tr) 2001-05-21

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00205T TR200100205T2 (tr) 1998-07-21 1999-06-18 Aterosklerotik lezyonların tedavisi için ACAT ve MMP inhibitörlerinin birlikte uygulanması.

Country Status (25)

Country Link
EP (1) EP1098662A2 (tr)
JP (1) JP2002521328A (tr)
KR (1) KR20010083134A (tr)
CN (1) CN1310629A (tr)
AP (1) AP2001002035A0 (tr)
AU (1) AU4701799A (tr)
BG (1) BG105162A (tr)
BR (1) BR9912296A (tr)
CA (1) CA2335062A1 (tr)
CZ (1) CZ2001126A3 (tr)
EA (1) EA200100153A1 (tr)
EE (1) EE200100046A (tr)
HR (1) HRP20010055A2 (tr)
HU (1) HUP0102880A3 (tr)
ID (1) ID30030A (tr)
IL (1) IL140982A0 (tr)
IS (1) IS5809A (tr)
NO (1) NO20010291L (tr)
OA (1) OA11584A (tr)
PL (1) PL346011A1 (tr)
SK (1) SK502001A3 (tr)
TR (1) TR200100205T2 (tr)
WO (1) WO2000004892A2 (tr)
YU (1) YU3501A (tr)
ZA (1) ZA200100294B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
AU2003267991B2 (en) * 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
ATE207891T1 (de) * 1996-05-17 2001-11-15 Warner Lambert Co Biphenylsulfonamid matrix metalloproteinase inhibitoren
KR20000068414A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도

Also Published As

Publication number Publication date
CZ2001126A3 (cs) 2002-01-16
HRP20010055A2 (en) 2002-04-30
ID30030A (id) 2001-11-01
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
HUP0102880A2 (en) 2002-06-29
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A2 (en) 2000-02-03
WO2000004892A3 (en) 2000-05-18
ZA200100294B (en) 2002-01-10
AU4701799A (en) 2000-02-14
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
HUP0102880A3 (en) 2002-11-28
NO20010291L (no) 2001-01-18
CN1310629A (zh) 2001-08-29
EE200100046A (et) 2002-06-17
EP1098662A2 (en) 2001-05-16
IS5809A (is) 2001-01-12
EA200100153A1 (ru) 2001-08-27
YU3501A (sh) 2005-06-10
AP2001002035A0 (en) 2001-03-31
PL346011A1 (en) 2002-01-14
KR20010083134A (ko) 2001-08-31
SK502001A3 (en) 2002-06-04
BG105162A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
TR200003808T2 (tr) Bir cox-2 inhibitörü içeren farmasötik kombinasyon
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
TR200101531T2 (tr) Kanala sahip olan emici eşya
NO20003565D0 (no) Sulfonylaminoderivater som hemmer matriks-nedbrytende metalloproteinaser
DE69738186D1 (de) Erweiterungsstation für einen tragbaren Computer, der eine zusätzliche Batterie enthält
EP1061800A4 (en) COMPOSITIONS AND METHODS FOR MODULATING THE VASCULARIZATION
DE59908600D1 (de) Substituierte benzimidazole und ihre verwendung als parp inhibitoren
NO20011023D0 (no) Arylpiperaziner og anvendelse derav som metalloproteinase inhiberende midler (MMP)
DE10085269T1 (de) Ultradünne elektrochemische Energiespeichervorrichtungen
DE69910480D1 (de) Sekundärbatterie Stromquelle
DE69837843D1 (de) Stromunterbrecher für elektrochemische zellen
DE69941723D1 (de) Kombinierte standby-instrumente für flugzeug
TR200200673T2 (tr) Rinovirüs enfeksiyonlarında csaıd'lerin kullanılması
TR199903287T2 (tr) Matriks metaloproteinazlarinin ters hidroksamat inhibitörleri.
NO993587L (no) Sulfonamid-metalloprotease-inhibitorer
TR200002877T2 (tr) Sülfonamid türevleri
ATE234812T1 (de) Integrin antagonisten
NO995267D0 (no) Leptin som en inhibitor av tumorcelleprofilering
TR200102259T2 (tr) Yeni oral formülasyon
DE69903866D1 (de) Multiplizierer mit niedriger Leistung für CPU und DSP
YU3501A (sh) Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze
DE60016297D1 (de) Selbsttestarchitektur für den Überdrehzahlschutz- und den Notausschaltkreislauf
DE69823101D1 (de) Energieverteilungssystem für Halbleiterchip
TR199900762T2 (tr) Stresle aktiflestirilen protein kinazlarinin engellenme yöntemi.
DE69835938D1 (de) Positives aktives Material für alkalische Speicherbatterie